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Abstract
Background and Objective The safety, tolerability, and
pharmacokinetics of the once-daily human glucagon-like
peptide-1 (GLP-1) analog liraglutide have been evaluated
in pediatric patients aged greater than 10 years with type 2
diabetes (T2D). In this study, a population pharmacokinetic
analysis was compared to the pediatric pharmacokinetic
data with those from two clinical pharmacology trials in
adults with T2D.
Methods A one-compartment pharmacokinetic model
previously found to adequately describe the pharmacoki-
netics of liraglutide in adults with T2D was applied to the
evaluation of 13 pediatric subjects (10–17 years of age)
with T2D. Steady-state estimates for apparent clearance
(CL/F) for individual subjects and corresponding dose were
used to derive the area under the plasma–concentration
time curve from 0–24 h (AUC24) and investigate dose
proportionality in the pediatric trial. A covariate analysis
evaluated the effects of body weight, gender, and age
category (pediatric/adult) on liraglutide exposure.
Results Dose proportionality in the dose range of
0.3–1.8 mg was indicated by the model-derived AUC24
slope: 1.05 (95 % CI 0.96–1.15). Consistent with findings
from adult trials, body weight and gender were relevant
covariates for liraglutide exposure in the pediatric popu-
lation. The CL/F estimates, and thus exposure, for the
pediatric subjects with T2D were similar to those in the
adult trials.
Conclusion Based on this population pharmacokinetic
analysis, the liraglutide dose regimen that was found to be
clinically effective in adults is predicted to achieve the
same range of exposure in the pediatric population
(10–17 years of age) with a pre-trial body weight range of
57–214 kg.
Key Points
This model predicts that the liraglutide dose regimen
used in adults will result in the same range of
exposures in the pediatric population (10–17 years)
with type 2 diabetes (T2D).
This pharmacokinetic analysis of liraglutide in
pediatric subjects with T2D could help broaden the
range of treatment options for this population.
1 Introduction
The human glucagon-like peptide-1 (GLP-1) analog
liraglutide is currently approved for the treatment of
adults with type 2 diabetes (T2D). Clinical trials in adult
subjects with T2D demonstrated that liraglutide 1.2 mg
and 1.8 mg (administered alone or in combination with
other oral antidiabetic drugs and/or insulin) improved
glycemic control (mean decrease in glycated hemoglobin
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[HbA1c] up to -1.5 %), reduced body weight (mean
weight loss up to -3.4 kg for liraglutide 1.8 mg and
-2.9 for liraglutide 1.2 mg) and had an acceptable safety
and tolerability profile, with the most prevalent adverse
events being gastrointestinal in nature (mainly mild,
transient nausea) [1–7]. The pharmacokinetics of lira-
glutide in adults showed dose–exposure proportionality
and properties consistent with once-daily dose adminis-
tration. While advanced age ([65 years), race, and eth-
nicity did not affect drug exposure in adults, body weight
and gender were identified as relevant covariates for
liraglutide exposure [8]; however, these characteristics
did not affect clinical response to the 1.2 mg and 1.8 mg
doses.
The prevalence of T2D in youth is increasing [9].
Currently, in addition to the emphasis on lifestyle
change, metformin and insulin are the only pharmaco-
logical treatments approved for the medical management
of pediatric subjects with this disease [10]. However, as
metformin therapy alone is often unable to maintain
glycemic control in pediatric subjects [11], there is a
growing need to broaden the range of treatment options
for this population.
A recent clinical trial was the first to evaluate the
safety, tolerability, and pharmacokinetics of liraglutide
in pediatric subjects (10–17 years of age) with T2D
[12]. While the pharmacokinetic profile of liraglutide in
pediatric subjects was consistent with the profile in
adults, there were several limitations for the analysis of
pharmacokinetic data in the study [12]. The pediatric
population with T2D is still relatively small compared
with the adult population, which hindered recruitment
of pediatric patients into this trial. Additionally, a
minimized number and volume of blood samples
(sparse sampling) and time limits on trial participation
can be encountered [12]. Given these limitations, a
traditional non-compartmental approach to data analysis
cannot always be employed to evaluate pediatric
exposure or liraglutide dose–exposure proportionality.
However, these limitations can be overcome by using
the population pharmacokinetics analysis approach that
allows the comparison of drug pharmacokinetics from
pediatric trials with those previously obtained in adults
[13].
In this study, in order to compare the pharmacokinetics
of liraglutide in children and adolescents (referred to herein
as ‘pediatric’) and adult subjects, and to determine whether
the adult dosing regimen is appropriate for future clinical
trials in this pediatric population, we undertook a popula-
tion pharmacokinetic analysis comparing the data from the
above-mentioned pediatric trial with liraglutide with those
from two previously published liraglutide trials in adult
subjects with T2D [14, 15].
2 Methods
2.1 Data Sources Used to Populate
the Pharmacokinetics Model
Population demographics and pharmacokinetic data from
previously reported clinical trials (one in pediatric subjects
[Trial 1, n = 13 subjects] and two in adult subjects [Trials
2 and 3, n = 12 and n = 32 subjects, respectively]) were
used as data sources for this population pharmacokinetic
analysis (see Online Resource Table 1 and, Figs. 1, 2) [12,
14, 15]. The adult trials were pre-selected and were chosen
as they included adults with T2D and had pharmacokinetic
sampling at steady-state (24 h). Trial 3 had a lower pro-
portion of women compared with Trials 1 and 2 (28 % vs.
62 and 50 %, respectively). The median body weight of
pediatric subjects (Trial 1) was greater than the weight of
adult subjects in Trials 2 and 3 (106 kg vs. 83 and 96 kg,
respectively); this was true mainly because of one outlier
(baseline body weight of 214 kg), which commonly occurs
with small sample sizes. The adult trials were selected as
comparators prior to the unblinding of the pediatric trial
due to the similarity of their study populations (all subjects
with T2D) and the availability of full steady-state phar-
macokinetic profiles with liraglutide 1.8 mg. All of these
trials were conducted in accordance with the Declaration of
Helsinki [16] and adhered to the Good Clinical Practice
Guidelines [17], with subjects (or their legal age repre-
sentatives) providing written informed consent. Pediatric
subjects treated in Europe also provided written assent.
2.1.1 Pediatric Trial
The pediatric trial (Trial 1) was a clinical pharmacology,
randomized, multicenter, double-blind, placebo-controlled
trial of once-daily liraglutide in pediatric subjects
(10–17 years of age) with T2D (trial registration number:
NCT00943501). Details of trial design and assessments
have been described previously [12] and are briefly sum-
marized below. Eligible participants had HbA1c 6.5–11 %
and fasting plasma glucose (FPG) 6.1–13.3 mmol/L
(110–240 mg/dL). The first four participants had different
glycemic inclusion criteria (HbA1c 7–10 % and FPG
7.2–12.2 mmol/L [130–220 mg/dL]), which were later
broadened to those above in order to facilitate recruitment.
Additional eligibility criteria were: body mass index (BMI)
[85th percentile for their age and gender; subjects were
treated with diet and exercise alone or in combination with
a stable dose of metformin for at least 4 weeks before
screening. The majority of subjects were post-pubertal
based on Tanner stage; only two subjects in the liraglutide
group were pre-pubertal (at Tanner stage I or II). Subjects
with impaired renal function defined as serum-creatinine
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greater than the upper reference range for age in children
were excluded.
Liraglutide dose was increased weekly (with 1 week at
each dose level) starting at 0.3 mg/day to doses of 0.6, 0.9,
1.2, and 1.8 mg/day or corresponding placebo over
5 weeks, based on tolerability and FPG (average of three
consecutive measurements[6.1 mmol/L [110 mg/dL]). If
the dose was not increased, participants continued on their
highest attained dose level for the rest of the treatment
period. The safety and side effect profile of liraglutide in
pediatric subjects with T2D was similar to that in adults;
gastrointestinal adverse events were reported most com-
monly [12]. Samples for pharmacokinetic assessments
were drawn on the last day of the week before dose esca-
lation at liraglutide doses of 0.3 mg (week 1), 0.6 mg
(week 2), 1.2 mg (week 4) and after the final drug dose for
1.8 mg (week 5). The first four participants had a 24-h
blood sampling schedule during weeks 1, 2, and 4, which
was amended to a 13-h schedule for the remaining partic-
ipants, in order to reduce their time spent in the clinic.
Blood samples were taken 15 min before drug adminis-
tration and at 2, 5, 8, 10, and 13 h post-dosing. Blood
samples were also taken at 24, 48, and 72 h after admin-
istration of the final drug dose in week 5 (1.8 mg or the
highest attained dose) to determine the concentration of
liraglutide during the 0–72 h post-dose period.
Of the 14 subjects randomized to liraglutide, one subject
withdrew prior to data collection due to procedural issues
and therefore did not contribute any pharmacokinetic data.
Thus, data for 13 subjects treated with liraglutide were
included in the population pharmacokinetic analysis. One
subject remained at liraglutide 0.3 mg throughout the trial
period, and three subjects did not escalate beyond liraglu-
tide 0.6 mg; these subjects continued on these dose levels
until the end of the trial. One subject self-administered
liraglutide 1.5 mg by mistake for 6 days prior to the day of
pharmacokinetic sampling, whereas drug doses for two
subjects were escalated from 0.6 mg to 0.9 mg by mistake
on the day of pharmacokinetic blood sampling. Although
these doses (1.5 mg and 0.9 mg) deviated from the trial
protocol, liraglutide concentration measurements from
these samples were included in this population pharmaco-
kinetic analysis, even if the subjects were not in steady-
state. Information regarding the amount of drug and time of
administration was available for all doses taken during the
trial [12].
2.1.2 Adult Trials
Trial 2 (NCT00993304) was a pharmacokinetic study that
examined the effect of steady-state liraglutide 1.8 mg on
postprandial lipid levels [14]. It was a randomized, double-
blind, placebo-controlled, two-period, crossover trial in
adult subjects with T2D with HbA1c between 6.5 and 10 %
and BMI between 18.5 and 40 kg/m2, and subjects with
impaired renal function, defined as creatinine clearance
\60 mL/min, were excluded. Blood samples were drawn at
steady-state after subjects had received liraglutide 1.8 mg
for 1 week. In addition, serial samples were taken over a
60-h period after the administration of the last dose.
Pharmacokinetic sampling and profiling details for the
liraglutide 1.8 mg dose are shown in Table 1.
Trial 3 (NCT00873223) was an open-label trial inves-
tigating the pharmacokinetics and pharmacodynamics of a
single dose of insulin detemir and steady-state liraglutide
1.8 mg in adult subjects with T2D [15]. Subjects with
HbA1c between 7 and 9.5 % were eligible for this trial, and
subjects with impaired renal function, defined as serum
creatinine C1.5 mg/dL for males and C1.3 mg/dL for
females, were excluded. Only pharmacokinetic data
obtained after administration of liraglutide 1.8 mg alone
for 1 week, with serial blood samples drawn 0–24 h after
the last dose of liraglutide 1.8 mg, were used in the present
analysis (Table 1).
For all three trials, the levels of liraglutide in plasma
samples were measured using a validated enzyme-linked
immunosorbent assay (ELISA) method [18].
2.2 Pharmacokinetic Model
A one-compartment pharmacokinetic model with first-
order absorption and elimination parameters (absorption
rate constant [ka], apparent clearance [CL/F], and apparent
volume of distribution [Vd/F]) was previously found to
adequately describe liraglutide pharmacokinetic data in
adult subjects with T2D [8]. In order to demonstrate that
the model developed previously for adults with T2D would
be applicable for the study of pediatric subjects, model
qualification was performed by means of goodness-of-fit
plots as part of the analysis, following the recommenda-
tions in the US FDA guidance for industry regarding
population pharmacokinetic analyses [19]. The pharmaco-
kinetic model was fitted to the pooled data from the three
trials to obtain parameter estimates for this particular
dataset. Between-subject variability parameters were
included for CL/F and Vd/F (data not shown). Residual
error was described using a proportional error model.
Estimates for steady-state drug CL/F for each individual
pediatric subject and the corresponding dose level were
used to derive area under the plasma–concentration time
curve from 0–24 h (AUC24) [i.e. liraglutide exposure]
using the following calculation: AUC24 = dose (in nmol)/
(CL/F); AUC24 was used to evaluate the dose proportion-
ality for liraglutide in the dose range 0.3–1.8 mg. Esti-
mated CL/F and the derived AUC24 for pediatric and adult
subjects were compared to support the selection of starting
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and maintenance doses in future pediatric clinical trials.
Model-derived liraglutide concentration–time profiles for
those pediatric (Trial 1) and adult (Trials 2 and 3) subjects
who received the 1.8 mg dose were compared.
The effect of pre-selected covariates (body weight,
gender, and age category [i.e. pediatric/adult]) on liraglu-
tide exposure was investigated using a pooled dataset from
the three trials (Trials 1, 2, and 3). By pooling all data, the
pharmacokinetic model allowed for testing the effect of all
covariates simultaneously. The parameterization of the
covariates (power model) is as shown in Online Resource
Table 1. Body weight and gender were chosen because
they were previously identified as important covariates for
liraglutide exposure in adults, although neither parameter
impacted clinical response to the liraglutide 1.2 and 1.8 mg
doses [8]. Due to a narrow age range in pediatric subjects
(10–17 years), and an age gap between the oldest pediatric
subjects (17 years) and the youngest adult subject
(33 years), the inclusion of age as a continuous covariate
was not feasible (data not shown). A covariate modeling
approach emphasizing parameter estimation rather than
stepwise hypothesis testing was implemented [20, 21],
where the impact of each covariate was assessed in a full
model estimation approach by examining the change in
mean (90 % confidence interval [CI]) AUC24 relative to a
reference subject which represented a composite of selec-
ted reference covariates (a 90 kg adult female). Body
weight of 90 kg was chosen as it represents the approxi-
mate average body weight for patients with T2D in the trial
populations analyzed here. For discrete parameters, one of
the parameters was selected for gender (i.e. female) and
age group (i.e. adult). Covariate effects were considered
relevant for the exposure if the 90 % CIs were outside the
range of bioequivalence limits (0.8–1.25) [20].
2.3 Software
NONMEM 7.1.2 software (ICON Development Solutions,
Ellicott City, MD, USA) was used for all population
pharmacokinetic analyses, and S-plus, 8.0 (TIBCO, Palo
Alto, CA, USA) and R (Revolution R Enterprise 6.0) was
used for data processing and graphical analyses.
3 Results
A goodness-of-fit plot was used to compare the observed
and model-derived liraglutide concentration–time profiles
in the pediatric trial at each dose level (0.3, 0.6, 1.2, and
1.8 mg; Fig. 1). The large degree of overlap between the
observed and model-derived concentrations indicated that
the current model could adequately describe liraglutide
pharmacokinetics in pediatric subjects with T2D. Addi-
tional goodness-of-fit plots are shown in Online Resource
Figs. 3 and 4.
In order to confirm pediatric dose proportionality, esti-
mates of CL/F for each individual and the corresponding
liraglutide dose level were used to derive AUC24. In the
pediatric population, model-estimated liraglutide exposure
(AUC24) increased proportionally with increasing
Table 1 Data sources for the population pharmacokinetic analysis (subject demographics and pharmacokinetic sampling details)
Trial 1 (NCT00943501) Trial 2 (NCT00993304) Trial 3 (NCT00873223)
Population Pediatric T2D Adult T2D Adult T2D
No. of subjects 13 12 32
Female [n (%)] 8 (62) 6 (50) 9 (28)
Age range, years 10–17 54–73 33–68
Body weight, kg [median (range)] 106 (57–214) 83 (72–104) 96 (58–140)
Liraglutide doses with PK assessment 0.3, 0.6, 1.2, 1.8a 1.8 1.8
PK sampling times (h) -0.25, 2, 4, 8, 10, 11,
12, 14, 24b
-0.25, 2, 5, 8, 10, 13b
-0.25, 4, 6, 8, 10, 12, 14, 16, 24,
36, 48, 60
0, 2, 4, 6, 8, 9, 10, 11, 12, 14,
16, 18, 24
Mean total number of PK samples per subject
during the trial (n)
25c 12 13
PK profiles per subject (n) 4 1 1
Body weight was measured at randomization for Trial 1 and at sampling time for Trials 2 and 3
PK pharmacokinetic, T2D type 2 diabetes
a Evaluation of liraglutide pharmacokinetics at 0.9 mg and 1.5 mg doses was not specified in the trial protocol but represents protocol deviations
due to mistakes in drug dosing (subject) and the timing of pharmacokinetic blood sampling (site)
b The first four subjects had a 24-h blood sampling schedule. Following a protocol amendment which aimed to reduce the burden on the
remaining subjects, the blood sampling period was changed from 24 to 13 h
c Each patient had a total of four pharmacokinetic sampling sessions (at the end of weeks 1, 2, 4, and 5)
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liraglutide dose (0.3–1.8 mg; Fig. 2). The geometric mean
(95 % CI) exponent was 1.05 (0.96–1.15); the inclusion of
1.0 in the 95 % CI indicated dose proportionality, consis-
tent with previous findings in adults [8], also strongly
supported dose proportionality.
Body weight and gender have been previously identified
as important covariates for liraglutide exposure in adults
[8]. In order to determine whether these factors also
affected liraglutide exposure in pediatric subjects, the
impact of these covariates, as well as age category (pedi-
atric vs. adult), was investigated by examining the mean
AUC24 (90 % CI) relative to a reference subject (a 90 kg
adult female). Similar to previous observations in adults,
both body weight and gender had a pharmacokinetically
relevant impact on mean liraglutide exposure. The rele-
vance of the identified covariates (body weight and gender)
for the pediatric population was confirmed in a sensitivity
analysis which did not include adult data (data not shown).
Age group (pediatric vs. adult) was not considered a
pharmacokinetically relevant factor since it was of minor
magnitude (10 % decrease in AUC24 compared with an
adult subject of the same weight and gender), although the
90 % CI (0.78–1.03) was slightly outside the 80–125 %
range (Fig. 3). AUC24 decreased with increasing body
weight; geometric mean AUC24 was 64 % higher at the
lowest observed body weight (53 kg) and 56 % lower at
the highest observed body weight (216 kg) compared with
the exposure at a reference body weight of 90 kg (Fig. 3).
Furthermore, AUC24 was lower for males; a 31 % lower
drug exposure compared with the reference female subject
of the same body weight was observed. The inclusion of
covariates reduced between-subject variability in CL/F by
50 % compared with the base model without covariates.
At the liraglutide 1.8 mg dose, the CL/F estimate for
pediatric subjects was similar to that in the two adult trials
(median [range, L/h] 1.55 [0.67–3.83], 0.91 [0.59–2.35],
and 1.48 [1.04–3.72] for Trials 1, 2, and 3, respectively),
leading to an overlapping range of estimated AUC24 values
following the 1.8 mg dose in pediatric and adult subjects
(Fig. 4a). The range of estimated AUC24 in pediatric sub-
jects used in this analysis as well as in the dose propor-
tionality evaluation (Fig. 2) was comparable to the range in
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Fig. 1 Observed and model-derived liraglutide concentration profiles
in the pediatric population by dose level. Figures with bars geometric
mean (95% confidence interval) of the observed liraglutide concen-
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Fig. 2 Dose proportionality test based on model-estimated AUC24,
which, in turn, was derived from estimated CL/F. Solid line represents
geometric mean AUC24, as estimated by the linear mixed-effects
model of log (AUC24) versus log (dose). Model-derived AUC24 slope:
1.05 [0.96–1.15]95 % CI. AUC area under the plasma–concentration
time curve, AUC24 AUC from zero to 24 h, CL/F apparent clearance,
CI confidence interval
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Relative exposure (AUC)
Liraglutide – Forest plot of covariate effects









Fig. 3 Geometric mean ratios and 90 % CI of effect of demographic
covariates (gender, body weight, and age group) on AUC24 relative to
a reference subject (90 kg adult female). The solid line represents the
ratio of 1 (i.e. no pharmacokinetic relevance). Broken lines delineate
the acceptance interval for bioequivalence (0.8–1.25); these limits
were used to determine drug exposure equivalence in this analysis.
AUC area under the plasma–concentration time curve, AUC24 AUC
from zero to 24 h, CI confidence interval
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The differences in CL/F between the two adult trials were
partly due to the differences in body weight and gender
distribution (see Table 1). As demonstrated in the covariate
analysis that identified body weight as a relevant factor for
explaining between-subject variability in liraglutide expo-
sure (Fig. 3), AUC24 decreased with increasing body
weight (Fig. 4a). Upon adjusting for possible confounding
by body weight and gender differences, liraglutide con-
centration–time profiles for pediatric and adult subjects
treated with the 1.8 mg dose appeared very similar
(Fig. 4b).
4 Discussion
Herein, we report the application of a population pharma-
cokinetic model to pharmacokinetic data from pediatric
subjects administered the subcutaneous GLP-1 agonist,
liraglutide, over a 5-week period. As in adults, this model
was able to describe well the observed concentrations of
liraglutide in pediatric subjects, indicating its suitability for
analysis of pediatric liraglutide pharmacokinetics. More-
over, dose proportionality across a range of doses was
observed in the pediatric population, as in adults [21]. The
liraglutide dose regimen used in adults is predicted to
achieve the same range of exposures in the tested pediatric
population. Thus, the results of this analysis support the use
of the same starting, escalation, and maintenance doses of
liraglutide currently recommended for adults in future
clinical trials in pediatric patients who have similar age and
body weight as the children investigated in this trial. As a
result, the adult dosing regimen is currently being used in
the ongoing liraglutide phase III trial (Ellipse), which is
investigating the efficacy and safety of liraglutide (added to
metformin) over 52 weeks in pediatric subjects with T2D.
Body weight and gender were previously identified in
adult trials as pharmacokinetically relevant covariates for
liraglutide exposure, although they did not impact clinical
response in patients with T2D, including exploratory
pharmacodynamic data from this study which showed
short-term improvement in glycemic control [8]. The
findings of the present analysis demonstrate that there is an
indication of the same covariates being relevant in the
pediatric population as in the adult population, with lower
liraglutide exposure observed with increasing body weight
and with male gender. The means and ranges of body
weight and BMI for the population in this trial exceed those
of reference standards for the same age group. However,
the population is representative of the population of ado-
lescents intended for treatment with liraglutide for T2D.
Additionally, while the reason for the difference in expo-
sure between male and female subjects is unknown, it is
consistent across populations and trials [22, 23]. The
model-estimated reduction in liraglutide exposure for male
subjects (31 %) in this analysis was comparable to previous
estimates in adults [8]. There were no signs of differences
in the exposure of liraglutide between the pediatric group
and adults in the present analysis.
While this population pharmacokinetic model can ade-
quately describe the pharmacokinetics of liraglutide in
pediatric subjects, it may have some limitations. The use of
a descriptive model limits the applicability of the findings
for liraglutide pharmacokinetics to pediatric subjects with
T2D of similar age (range 10–17 years) and weight
(57–214 kg). The population of children and adolescents
with T2D, in addition to being difficult to recruit and retain,
Adults (n=44)
Pediatrics (n=13)
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Fig. 4 a AUC24 versus body weight for liraglutide 1.8 mg once
daily, according to age category (pediatric subjects from Trial 1 vs.
adult subjects from Trials 2 and 3). The completely superimposed
lines show the model-predicted AUC24 versus body weight for
pediatric and adult subjects, respectively. The estimated AUC24 has
been normalized to a 1.8 mg dose for four pediatric subjects, reaching
a maximum dose of 0.3 (n = 1) or 0.6 mg (n = 3). b Model-derived
typical steady-state concentration–time profiles for pediatric and adult
subjects receiving 1.8 mg liraglutide. The figure shows results for
pediatric and adult populations with body weight and gender adjusted
(both populations with body weight of 90 kg and 50 % female gender
composition) in order to minimize confounding. AUC area under the
plasma–concentration time curve, AUC24 AUC from zero to 24 h
668 K. C. C. Petri et al.
have unique physical characteristics which separate them
from the typical adult population with T2D and therefore
mandate these confirmatory pharmacokinetic studies. In
addition, body composition varies with age until adulthood.
Thus, given these distinct characteristics, long-term studies
of GLP-1 efficacy in this population are required. It is
possible that drug exposure for younger and leaner subjects
may be different. Of note, since the prevalence of T2D is
very low in youth aged \10 years (0.01 cases per 1,000
individuals) and higher in older youths (0.42 cases per
1,000 individuals), it was a regulatory requirement to
investigate the pharmacokinetics of liraglutide in children
or adolescents aged[10 years [24]. These studies begin to
address the need for data that support the proposal that one
might ‘extrapolate’ effects of GLP-1 agonists into the
pediatric population. However, great variability in body
composition, as seen in this T2D population, may mitigate
against this possibility, requiring pharmacodynamic studies
to support these conclusions. Therefore, the Ellipse phase
III study is currently underway.
There were also some limitations of the covariate ana-
lysis. The low number of pediatric subjects results in rel-
atively few subjects in each subpopulation, leading to
larger confidence intervals and less certain conclusions
compared with larger datasets. Additionally, age was ana-
lyzed as a categorical covariate, as it was in the previous
analysis of adult data [8], due to the age distribution in the
joint population. This trial protocol allowed for subjects not
adhering to the planned liraglutide dosing escalation regi-
men; while the model accounts for the different dose lev-
els, there were fewer samples for the analysis of the
maximum liraglutide 1.8 mg dose than initially planned.
Furthermore, although the designs of the adult and pedi-
atric trials were different, the model focuses on steady-state
exposure (24 h), and thus the difference in design at the
end of the interval ([24 h) is of less importance and should
not influence the results of the analysis.
Both the FDA and the European Medicines Agency
(EMA) recognize the importance of model-based drug
development to improve decision making for effectiveness
and safety [19, 25]. Accordingly, we used a population
pharmacokinetic approach comparing the available pedi-
atric data with data from similar adult trial subjects (i.e.
subjects with T2D) to select the doses for the presently
ongoing 52-week phase III efficacy and safety trial in
pediatric subjects with T2D (NCT01541215). In this larger,
longer trial, population pharmacokinetics will be used to
determine whether the similar liraglutide exposure in
pediatric and adult subjects results in a similar clinical
response.
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